



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/12, C12Q 1/48, A61K 38/45		A2	(11) International Publication Number: WO 98/53050 (43) International Publication Date: 26 November 1998 (26.11.98)
(21) International Application Number: PCT/US98/10319 (22) International Filing Date: 20 May 1998 (20.05.98) (30) Priority Data: 08/861,338 21 May 1997 (21.05.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/861,338 (CIP) Filed on 21 May 1997 (21.05.97) (71) Applicants (for all designated States except US): THE CHILDREN'S MEDICAL CENTER CORPORATION [US/US]; 300 Longwood Street, Boston, MA 02115 (US). YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; Jabotinsky Street 46, P.O. Box 4279, 91042 Jerusalem (IL). (72) Inventor; and (75) Inventor/Applicant (for US only): BEN-SASSON, Shmuel, A. [IL/IL]; Epstein Street 3, 96555 Jerusalem (IL).		(74) Agents: BROOK, David, E. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02173 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: SHORT PEPTIDES WHICH SELECTIVELY MODULATE THE ACTIVITY OF SERINE/THREONINE KINASES (57) Abstract Disclosed are peptides which are peptide derivatives of the HJ loop of a serine/threonine kinase. The peptides can modulate the activity of the serine/threonine kinase. Also disclosed are methods of modulating the activity of a serine/threonine kinase in a subject by administering one of the peptides of the present invention.			

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

SHORT PEPTIDES WHICH SELECTIVELY MODULATE
THE ACTIVITY OF SERINE/THREONINE KINASES

RELATED APPLICATIONS

This application is a continuation-in-part of U.S.
5 Serial No.: 08/861,338, filed May 21, 1997, the entire
teachings of which are incorporated by reference.

BACKGROUND OF THE INVENTION

Serine/threonine kinases are a member of the
eukaryotic protein kinase superfamily. Enzymes of this
10 class specifically phosphorylate serine or threonine
residues of intracellular proteins and are important in
mediating signal transduction in multicellular
organisms. Many serine/threonine kinases occur as
intracellular proteins which take part in signal
15 transduction within the cell, including signal
transduction to the nucleus and the activation of other
proteins. Other serine/threonine kinases, such as G
protein-coupled receptor kinases, are found in cell
membranes and participate in trans-membrane signalling.

20 As such, phosphorylation of serine or threonine by
serine/threonine kinases is an important mechanism for
regulating intracellular events in response to
environmental changes. A wide variety of cellular
events are regulated by serine/threonine kinases. A few
25 examples include the ability of cells to enter and/or
complete mitosis, cellular proliferation, cellular
differentiation, the control of fat metabolism, immune
responses, inflammatory responses and the control of
glycogen metabolism.

30 Thus, agents which can modulate (increase or
decrease) the activity of serine/threonine kinases have

great potential for the treatment of a wide variety of diseases and conditions such as cancer, obesity, autoimmune disorders, inflammation and Type II diabetes.

SUMMARY OF THE INVENTION

5 It has now been found that short peptides which are derivatives of the HJ loop of a serine/threonine kinase can significantly affect the activities of cells expressing the serine/threonine kinase ("HJ loop" is defined hereinbelow). For example, the peptide
10 derivatives of the HJ loop of Raf and Polo inhibit the proliferation of bovine aortic cells and the transformed mouse cell lines MS1 and/or SVR cells *in vitro* at concentrations as low as 10 μ M (Example 2). Based on the aforementioned discoveries, novel peptides are
15 disclosed herein which are peptide derivatives of the HJ loop of serine/threonine kinases. Also disclosed are methods of identifying a peptide derivative of an HJ loop of a serine/threonine kinase which modulates the activity of said serine/threonine kinase. Methods of
20 modulating the activity of a serine/threonine kinase in a subject are also disclosed.

One embodiment of the present invention is a novel peptide which is a peptide derivative of the HJ loop of a serine/threonine kinase. The peptide comprises
25 between about five and about twenty amino acid residues or amino acid residue analogs and modulates the activity of the serine/threonine kinase. The N-terminus and/or C-terminus of the peptide can be substituted or unsubstituted. The peptide can be linear or cyclic.

30 Another embodiment of the present invention is a method of modulating the activity of a serine/threonine kinase in a subject. The method comprises administering a therapeutically effective amount of a peptide which is a derivative of an HJ loop of said serine/threonine
35 kinase, as described above.

Yet another embodiment of the present invention is a method of identifying a peptide which modulates the activity of a serine/threonine kinase. The method comprises providing a "test peptide" which has from
5 about five to about twenty amino acids or amino acid analogs and which is a peptide derivative of the HJ loop of said serine/threonine kinase. The test peptide is incubated with cells having a cellular activity or function under the control of said serine/threonine
10 kinase under conditions suitable for assessing the activity of the serine/threonine kinase. The activity of the serine/threonine kinase is assessed and compared with cells of the same cell type grown under the same conditions in the absence of the test peptide. A
15 greater or lesser activity compared with cells grown in the absence of the test peptide indicates that the test peptide modulates activity of the serine/threonine kinase.

The peptides of the present invention can be used
20 in the treatment of a wide variety of diseases caused by overactivity and underactivity of a STK. Examples include, but are not limited to, cancer, diabetes, obesity, diseases of the central nervous system, inflammatory disorders, autoimmune diseases and
25 cardiovascular diseases. The peptides of the present invention also have *in vitro* utilities, for example, in the generation of antibodies which specifically bind the serine/threonine kinase from which the peptide was derived. These antibodies can be used to identify cells
30 expressing the serine/threonine kinase and to study the intracellular distribution of the serine/threonine kinase. In addition, the peptides of the present invention can be used to identify and quantitate ligands which bind the HJ loop of the serine/threonine kinase
35 from which the peptide was derived.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a sequence illustrating the consensus sequence for amino acid one through amino acid ten of the HJ loop found among the family of serine/threonine kinases.

Figure 2 is a sequence illustrating the consensus sequence for amino acid one through amino acid twenty of the HJ loop cyclic AMP dependent protein kinase and protein kinase C.

Figure 3 is a Table illustrating the amino acid sequence of the HJ loop of the serine/threonine kinases RAF (SEQ ID NO.: 1), cyclic AMP dependent protein kinase (CAPK) (SEQ ID NO.: 2), protein kinase C (PKC) (SEQ ID NO.: 3), the G-receptor coupled protein kinases β 2-adrenergic receptor kinases 1 and 2 (bARK1.2) (SEQ ID NO.: 4), calmodulin dependent kinase (CaMK) (SEQ ID NO.: 5), polo kinases (SEQ ID NO.: 6), Akt/PKB (SEQ ID NO.: 7) and the G-protein coupled receptor kinases GRK1 (SEQ ID NO.: 8), GRK4 (SEQ ID NO.: 9), GRK5 (SEQ ID NO.: 10), GRK6 (SEQ ID NO.: 11) and GSK3 (SEQ ID NO.: 12). Also shown are examples of conservative substitutions in these amino acid sequences. An "*" indicates an aliphatic, substituted aliphatic, benzylic, substituted benzylic, aromatic or substituted aromatic ester of glutamic acid or aspartic acid.

Figure 4 is a Table illustrating the sequences of the peptides HJ-38 (SEQ ID NO.: 13), J-41 (SEQ ID NO.: 14), J-42 (SEQ ID NO.: 15), J-43 (SEQ ID NO.: 16), J-43.1 (SEQ ID NO.: 17), J-45 (SEQ ID NO.: 18), J-46 (SEQ ID NO.: 19), J-47 (SEQ ID NO.: 20), J-48 (SEQ ID NO.: 21) and J-29 (SEQ ID NO.: 22). All peptides are N-acetylated and C-amidated. "E!" indicates a benzyl ester of glutamic acid.

Figure 5 is a graph showing the percent inhibition of collagen production in fetal lung fibroblasts in the presence of increasing concentrations (μ M) of K048H101 (SEQ ID NO.: 24) relative to control. K048H101 is a

peptide derivative of the HJ loop of the serine/threonine kinase *ALK1*.

Figure 6 is a Table showing the sequences of exemplary peptide derivatives of the present invention and the serine/threonine kinases from whose HJ loop they are derived. The peptide derivatives shown in Figure 6 are K095H101 (SEQ ID NO.: 23); K048H101 (SEQ ID NO.: 24); K098H101 (SEQ ID NO.: 25); K099H101 (SEQ ID NO.: 26); K093H101 (SEQ ID NO.: 27); K014H101 (SEQ ID NO.: 28); K004H001 (SEQ ID NO.: 29); K004H002 (SEQ ID NO.: 30); K049H101 (SEQ ID NO.: 31); K050H101 (SEQ ID NO.: 32); K088H001 (SEQ ID NO.: 33); K088H101 (SEQ ID NO.: 34); K088H103 (SEQ ID NO.: 35); K088H104 (SEQ ID NO.: 36); K092H001 (SEQ ID NO.: 37); K018H101 (SEQ ID NO.: 38); K087H001 (SEQ ID NO.: 39); K087H101 (SEQ ID NO.: 40); K087H102 (SEQ ID NO.: 41); K087H103 (SEQ ID NO.: 42); K090H101 (SEQ ID NO.: 43); K091H001 (SEQ ID NO.: 44); K091H101 (SEQ ID NO.: 45); K107H001 (SEQ ID NO.: 46); K107H101 (SEQ ID NO.: 47); K107H102 (SEQ ID NO.: 48); K045H101 (SEQ ID NO.: 49); K045H102 (SEQ ID NO.: 50); K008H001 (SEQ ID NO.: 51); K008H101 (SEQ ID NO.: 52); K008H102 (SEQ ID NO.: 53); K008H103 (SEQ ID NO.: 54); K035H001 (SEQ ID NO.: 55); K035H101 (SEQ ID NO.: 56); K038H101 (SEQ ID NO.: 57); K038H102 (SEQ ID NO.: 58); K003H103 (SEQ ID NO.: 59); K003H104 (SEQ ID NO.: 60); K001H102 (SEQ ID NO.: 61); and K001H103 (SEQ ID NO.: 62).

DETAILED DESCRIPTION OF THE INVENTION

A serine/threonine kinase (hereinafter "STK") is an intracellular or membrane bound protein which uses the gamma phosphate of ATP or GTP to generate phosphate monoesters on the hydroxyl group of a serine or threonine residue. STKs have homologous "kinase domains" or "catalytic domains" which carry out this phosphorylation. Based on a comparison of a large number of protein kinases, it is now known that the

kinase domain of protein kinases, including STKs, can be divided into twelve subdomains, which are regions generally uninterrupted by large amino acid insertions and contain characteristic patterns of conserved residues (Hanks and Hunter, "The Eukaryotic Protein Kinase Superfamily", in Hardie and Hanks (ed.), *The Protein Kinase Facts Book, Volume I*, Academic Press, Chapter 2, 1995. These subdomains are referred to as Subdomain I through Subdomain XII.

10 The "HJ loop" referred to herein is found within the kinase domain of STKs between the middle of Subdomain IX and the middle of Subdomain X. Because of the high degree of homology found in the subdomains of different protein kinases, including STKs, the amino acid sequences of the domains of different STKs can be aligned. Thus, the HJ loop of a STK can be defined by reference to the amino acid sequence of a prototypical protein kinase, for example PKA-C α , and can be said to correspond to a contiguous sequence of about twenty amino acid residues found between about amino acid 229 and 248 of PKA-C α .

A second definition of the HJ loop of a STK, which is complementary to the definition provided in the proceeding paragraph, can be made by reference to the three dimensional structure of the kinase domain of STKs. The kinase domain of STKs has been found to contain at least nine alpha helices, referred to as helix A through helix I (Tabor et al., *Phil. Trans. R. Soc. Lond. B*340:315 (1993), Mohammadi et al., *Cell* 86:577 (1996) and Hubbard et al., *Nature* 372:746 (1994)). The HJ loop is a contiguous sequence of about twenty amino acids beginning within the F helix about five amino acids residues from the N-terminus of the F helix and extending about five amino acid residues into the G helix.

Optionally, the C-terminus or the N-terminus of the peptides of the present invention, or both, can be

substituted with a carboxylic acid protecting group or an amine protecting group, respectively. Suitable protecting groups are described in Green and Wuts, "Protecting Groups in Organic Synthesis", John Wiley and Sons, Chapters 5 and 7, 1991, the teachings of which are incorporated herein by reference. Preferred protecting groups are those which facilitate transport of the peptide into a cell, for example, by reducing the hydrophilicity and increasing the lipophilicity of the peptide. Examples of N-terminal protecting groups include acyl groups ($-\text{CO}-\text{R}_1$) and alkoxy carbonyl or aryloxy carbonyl groups ($-\text{CO}-\text{O}-\text{R}_1$), wherein R_1 is an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or a substituted aromatic group. Specific examples of acyl groups include acetyl, (ethyl)-CO-, n-propyl-CO-, iso-propyl-CO-, n-butyl-CO-, sec-butyl-CO-, t-butyl-CO-, phenyl-CO-, substituted phenyl-CO-, benzyl-CO- and (substituted benzyl)-CO-. Examples of alkoxy carbonyl and aryloxy carbonyl groups include $\text{CH}_3\text{-O-CO-}$, (ethyl)-O-CO-, n-propyl-O-CO-, iso-propyl-O-CO-, n-butyl-O-CO-, sec-butyl-O-CO-, t-butyl-O-CO-, phenyl-O-CO-, substituted phenyl-O-CO- and benzyl-O-CO-, (substituted benzyl)-O-CO-. The carboxyl group at the C-terminus can be protected, for example, as an amide (i.e., the hydroxyl group at the C-terminus is replaced with $-\text{NH}_2$, $-\text{NHR}_2$ and $-\text{NR}_2\text{R}_3$) or ester (i.e. the hydroxyl group at the C-terminus is replaced with $-\text{OR}_2$). R_2 and R_3 are independently an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aryl or a substituted aryl group. In addition, taken together with the nitrogen atom, R_2 and R_3 can form a C4 to C8 heterocyclic ring with from about 0-2 additional heteroatoms such as nitrogen, oxygen or sulfur. Examples of suitable heterocyclic rings include piperidinyl, pyrrolidinyl, morpholino, thiomorpholino or piperazinyl. Examples of C-terminal protecting groups include $-\text{NH}_2$, $-\text{NHCH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{NH}(\text{ethyl})$, $-\text{N}(\text{ethyl})_2$, -

N(methyl)(ethyl), -NH(benzyl), -N(C1-C4 alkyl)(benzyl), -NH(phenyl), -N(C1-C4 alkyl)(phenyl), -OCH₃, -O-(ethyl), -O-(n-propyl), -O-(n-butyl), -O-(iso-propyl), -O-(sec-butyl), -O-(t-butyl), -O-benzyl and -O-phenyl.

5 A "peptide derivative of the HJ loop" includes a peptide having the amino acid sequence of the HJ loop. A "peptide derivative of the HJ loop" also includes, for example, a subsequence of the HJ loop of the STK. A subsequence is a contiguous sequence of from about five
10 to about twenty amino acids or amino acid residues found within a larger sequence. Thus, a subsequence of the HJ loop is a contiguous sequence of from about five to about twenty amino acids or amino acid residues found within the HJ loop. A subsequence of the HJ loop can
15 also be referred to as a "fragment" of the HJ loop.

 A "peptide derivative" also includes a peptide having a "modified sequence" in which one or more amino acids in the original sequence or subsequence have been substituted with a naturally occurring amino acid or
20 amino acid analog (also referred to as a "modified amino acid"). In one aspect of the present invention, the peptide derivative has an sequence corresponding to a subsequence of the HJ loop of a STK, with the proviso that any one amino acid residue in the peptide
25 derivative can differ from the corresponding amino acid residue in the subsequence. For example, if the subsequence is [AA₁]-[AA₂]-[AA₃]-[AA₄]-[AA₅], then the peptide derivative can be [AA₁']-[AA₂]-[AA₃]-[AA₄]-[AA₅], [AA₁]-[AA₂']-[AA₃]-[AA₄]-[AA₅], [AA₁]-[AA₂]-[AA₃']-[AA₄]-
30 [AA₅], [AA₁]-[AA₂]-[AA₃]-[AA₄']-[AA₅] and [AA₁]-[AA₂]-[AA₃]-[AA₄]-[AA₅'], wherein [AA'] is a naturally occurring or modified amino acid different from [AA]. In another aspect of the present invention, the peptide derivative has a sequence corresponding to a subsequence of the HJ
35 loop of an STK, with the proviso that any two amino acid residues in the peptide derivative can differ from the corresponding amino acid residue in the subsequence.

An "amino acid residue" is a moiety found within a peptide and is represented by -NH-CHR-CO-, wherein R is the side chain of a naturally occurring amino acid. When referring to a moiety found within a peptide, the terms "amino acid residue" and "amino acid" are used interchangeably in this application. An "amino acid residue analog" includes D or L residues having the following formula: -NH-CHR-CO-, wherein R is an aliphatic group, a substituted aliphatic group, a benzyl group, a substituted benzyl group, an aromatic group or a substituted aromatic group and wherein R does not correspond to the side chain of a naturally-occurring amino acid. When referring to a moiety found within a peptide, the terms "amino acid residue analog" and "amino acid analog" are used interchangeably in this application.

As used herein, aliphatic groups include straight chained, branched or cyclic C1-C8 hydrocarbons which are completely saturated, which contain one or two heteroatoms such as nitrogen, oxygen or sulfur and/or which contain one or more units of unsaturation. Aromatic groups include carbocyclic aromatic groups such as phenyl and naphthyl and heterocyclic aromatic groups such as imidazolyl, indolyl, thienyl, furanyl, pyridyl, pyranal, pyranol, oxazolyl, benzothienyl, benzofuranyl, quinolinyl, isoquinolinyl and acridintyl.

Suitable substituents on an aliphatic, aromatic or benzyl group include -OH, halogen (-Br, -Cl, -I and -F) -O(aliphatic, substituted aliphatic, benzyl, substituted benzyl, aryl or substituted aryl group), -CN, -NO₂, -COOH, -NH₂, -NH(aliphatic group, substituted aliphatic, benzyl, substituted benzyl, aryl or substituted aryl group), -N(aliphatic group, substituted aliphatic, benzyl, substituted benzyl, aryl or substituted aryl group)₂, -COO(aliphatic group, substituted aliphatic, benzyl, substituted benzyl, aryl or substituted aryl group), -CONH₂, -CONH(aliphatic, substituted aliphatic

group, benzyl, substituted benzyl, aryl or substituted aryl group)), -SH, -S(aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group) and -NH-C(=NH)-NH₂. A substituted
5 benzylic or aromatic group can also have an aliphatic or substituted aliphatic group as a substituent. A substituted aliphatic group can also have a benzyl, substituted benzyl, aryl or substituted aryl group as a substituent. A substituted aliphatic, substituted
10 aromatic or substituted benzyl group can have one or more substituents.

Suitable substitutions for amino acid residues in the sequence of an HJ loop or a subsequence of an HJ loop include conservative substitutions which result in
15 peptide derivatives which modulate the activity of a STK. A "conservative substitution" is a substitution in which the substituting amino acid (naturally occurring or modified) has about the same size and electronic properties as the amino acid being substituted. Thus,
20 the substituting amino acid would have the same or a similar functional group in the side chain as the original amino acid.

A "conservative substitution" also refers to utilizing a substituting amino acid which is identical
25 to the amino acid being substituted except that a functional group in the side chain is functionalized with a suitable protecting group. Suitable protecting groups are described in Green and Wuts, *"Protecting Groups in Organic Synthesis"*, John Wiley and Sons,
30 Chapters 5 and 7, 1991, the teachings of which are incorporated herein by reference. As with N-terminal and C-terminal protecting group, preferred protecting groups are those which facilitate transport of the peptide into a cell, for example, by reducing the
35 hydrophilicity and increasing the lipophilicity of the peptide, and which can be cleaved *in vivo*, either by hydrolysis or enzymatically, inside the cell. (Ditter

et al., *J. Pharm. Sci.* 57:783 (1968); Ditter et al., *J. Pharm. Sci.* 57:828 (1968); Ditter et al., *J. Pharm. Sci.* 58:557 (1969); King et al., *Biochemistry* 26:2294 (1987); Lindberg et al., *Drug Metabolism and Disposition* 17:311
5 (1989); and Tunek et al., *Biochem. Pharm.* 37:3867 (1988), Anderson et al., *Arch. Biochem. Biophys.* 239:538 (1985) and Singhal et al., *FASEB J.* 1:220 (1987)).

Hydroxyl protecting groups include esters, carbonates and carbamate protecting groups. Amine protecting
10 groups include alkoxy and aryloxy carbonyl groups, as described above for N-terminal protecting groups. Carboxylic acid protecting groups include aliphatic, benzylic and aryl esters esters, as described above for C-terminal protecting groups. In one embodiment, the
15 carboxylic acid group in the side chain of one or more glutamic acid or aspartic acid residue in a peptide of the present invention is protected, preferably with as a methyl, ethyl, benzyl or substituted benzyl ester, more preferably as a benzyl ester.

20 Provided below are groups of naturally occurring and modified amino acids in which each amino acid in a group has similar electronic and steric properties. Thus, a conservative substitution can be made by substituting an amino acid with another amino acid from
25 the same group. It is to be understood that these groups are non-limiting, i.e. that there are additional modified amino acids which could be included in each group.

Group I includes leucine, isoleucine, valine,
30 methionine, serine, cysteine, threonine and modified amino acids having the following side chains: ethyl, n-butyl, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CHOHCH}_3$ and $-\text{CH}_2\text{SCH}_3$. Preferably, Group I includes leucine, isoleucine, valine and
35 methionine.

Group II includes glycine, alanine, valine, serine, cysteine, threonine and a modified amino acid having an ethyl side chain. Preferably, Group II includes glycine and alanine.

5 Group III includes phenylalanine, phenylglycine, tyrosine, tryptophan, cyclohexylmethyl, and modified amino residues having substituted benzyl or phenyl side chains. Preferred substituents include one or more of the following: halogen,
10 methyl, ethyl, nitro, methoxy, ethoxy and -CN. Preferably, Group III includes phenylalanine, tyrosine and tryptophan.

Group IV includes glutamic acid, aspartic acid, a substituted or unsubstituted aliphatic, aromatic
15 or benzylic ester of glutamic or aspartic acid (e.g., methyl, ethyl, n-propyl iso-propyl, cyclohexyl, benzyl or substituted benzyl), glutamine, asparagine, CO-NH-alkylated glutamine or asparagine (e.g., methyl, ethyl, n-propyl and iso-
20 propyl) and modified amino acids having the side chain $-(CH_2)_3-COOH$, an ester thereof (substituted or unsubstituted aliphatic, aromatic or benzylic ester), an amide thereof and a substituted or unsubstituted N-alkylated amide thereof.
25 Preferably, Group IV includes glutamic acid, aspartic acid, methyl aspartate, ethyl aspartate, benzyl aspartate and methyl glutamate, ethyl glutamate and benzyl glutamate.

Group V includes histidine, lysine, arginine, N-
30 nitroarginine, β -cycloarginine, γ -hydroxyarginine, N-amidinocitruline and 2-amino-4-guanidinobutanoic acid, homologs of lysine, homologs of arginine and ornithine. Preferably, Group V includes histidine, lysine, arginine, and ornithine. A homolog of an

amino acid includes from 1 to about 3 additional methylene units in the side chain.

Group VI includes serine, threonine, cysteine and modified amino acids having C1-C5 straight or
5 branched alkyl side chains substituted with -OH or -SH. Preferably, Group VI includes serine, cysteine or threonine.

In another aspect, suitable substitutions for amino acid residues in the sequence of an HJ loop or a
10 subsequence of an HJ loop include "severe" substitutions which result in peptide derivatives which modulate the activity of a STK. Severe substitutions which result in peptide derivatives that modulate the activity of a STK are much more likely to be possible in positions which
15 are not highly conserved throughout the family of serine/threonine kinases than at positions which are highly conserved. Figure 1 shows the consensus sequence of the about first ten amino acids of the HJ loop of STKs. Figure 2 shows the consensus sequence of the
20 about twenty amino acids of the HJ loop of cyclic AMP dependent kinase and protein kinase C. Positions which are highly conserved among the STK family and the conserved amino acids generally found in those positions have been indicated. Positions which are not as highly
25 conserved among the STK family are indicated with an "X". Because D-amino acids have a hydrogen at a position identical to the glycine hydrogen side-chain, D-amino acids or their analogs can be substituted for the glycine at position 6 in Figure 1 or at positions 6
30 and 12 in Figure 2.

A "severe substitution" is a substitution in which the substituting amino acid (naturally occurring or modified) has significantly different size and/or electronic properties compared with the amino acid being
35 substituted. Thus, the side chain of the substituting

amino acid can be significantly larger (or smaller) than the side chain of the amino acid being substituted and/or can have functional groups with significantly different electronic properties than the amino acid being substituted. Examples of severe substitutions of this type include the substitution of phenylalanine or cyclohexylmethyl glycine for alanine, isoleucine for glycine, a D amino acid for the corresponding L amino acid or $\text{-NH-CH[(-CH}_2\text{)}_5\text{-COOH]-CO-}$ for aspartic acid. Alternatively, a functional group may be added to the side chain, deleted from the side chain or exchanged with another functional group. Examples of severe substitutions of this type include adding an amine or hydroxyl, carboxylic acid to the aliphatic side chain of valine, leucine or isoleucine, exchanging the carboxylic acid in the side chain of aspartic acid or glutamic acid with an amine or deleting the amine group in the side chain of lysine or ornithine. In yet another alternative, the side chain of the substituting amino acid can have significantly different steric and electronic properties than the functional group of the amino acid being substituted. Examples of such modifications include tryptophan for glycine, lysine for aspartic acid and $\text{-(CH}_2\text{)}_4\text{COOH}$ for the side chain of serine. These examples are not meant to be limiting.

Examples STKs whose activity can be modulated by peptide and peptide derivatives, as described herein, include, but are not limited to, STKs belonging to the following STK families: polo family (Glover et al., *J. Cell Biol.*, 135:1681 (1996)), Raf, mitogen-activated protein kinases (MAP kinases), Akt/PKB (Frank et al., *Cell* 88:435 (1997) and Hemmings et al., *Science* 275:628 (1997)) and G protein-coupled receptor kinases. Other suitable STKs include cyclic AMP (cAMP) dependent protein kinase, protein kinase C, calmodulin dependent kinase, glycogen synthase kinase-3 (GSK3) and cyclic GMP (cGMP) dependent protein kinase.

Suitable members of the polo family include, but are not limited to, Plk, Snk and Sak. Suitable members of the Raf family include, but are not limited to, Raf-1, A-Raf and B-Raf. Suitable G-protein dependent
5 kinases include, but are not limited to, β -adrenergic receptor kinases 1 and 2, rhodopsin kinase (GRK1), GRK4, GRK5 and GRK6. Suitable MAP kinases include, but are not limited to MAPK, MAPKK and MAPKKK. Also included are the protein kinase C isoforms, which include, but
10 are not limited to, isoforms designated as α , $\beta_{1/H}$, γ , δ , ϵ , $\eta(L)$, θ , μ , ξ , ι and λ .

The present invention includes peptides having amino acid sequences corresponding to the sequence found in the HJ loop of STKs, subsequences thereof and
15 modified subsequences thereof. Examples of suitable subsequences include, but are not limited to, sequences corresponding to [AA]₁ through [AA]₂₀, [AA]₃ through [AA]₁₀, [AA]₇ through [AA]₁₄, [AA]₁₁ through [AA]₁₈, [AA]₃ through [AA]₁₄, [AA]₇ through [AA]₁₈ and [AA]₃ through
20 [AA]₁₈ of the HJ loop of a STK, and subsequences thereof. Figure 3 shows the sequences of the HJ loop of the following STKs: RAF, cyclic AMP dependent kinase, protein kinase C, the G-protein-coupled receptor kinases β ARK 1 and 2 and GRK1, GRK4, GRK5 and GRK6, calmodulin
25 dependent kinase, polo, Akt/PKB and GSK3.

Figure 3 also provides a numbering scheme for the amino acid sequence in an loop. The amino acid at the N-terminus of the HJ loop is at position 1 and can be referred to as "[AA]₁". The next amino acid in the
30 sequence, referred to as "[AA]₂", is at position 2 and is followed by amino acids [AA]₃ through [AA]₂₀, which are at positions 3-20. Thus, a peptide 20-mer with an amino acid sequence [AA]₁ through [AA]₂₀ includes the twenty amino acids in the HJ loop. A peptide derivative of the
35 HJ loop with an amino acid sequence [AA]₃ through [AA]₁₀, as recited in the preceding paragraph, includes the

third amino acid through the tenth amino acid in said HJ loop.

The present invention also includes peptides having amino acid sequences corresponding to a modified
5 sequence or subsequence of the HJ loop of STKs and which modulate the activity of STKs including RAF, cyclic AMP dependent kinase, protein kinase C, the G-protein-coupled receptor kinases β ARK 1, β ARK2, GRK1 and GRKs4-6, calmodulin dependent kinase and polo. In one aspect,
10 one, two or more of the amino acids in the sequence or subsequence are modified with conservative substitutions; the substitutions can be in consensus positions, in non-consensus positions or in both. In another aspect, one, two or more of the amino acids in
15 the sequence or subsequence are modified with severe substitutions; the substitutions are preferably in non-consensus positions. Also included are the substitution of conserved glycine residues (e.g., position 6 in Figure 1 or positions 6 and 12 in Figure 2) with D-amino
20 acid residues or analogs thereof. Figure 3 also provides examples of conservative amino acid substitutions for the HJ loop of RAF, cyclic AMP dependent kinase, protein kinase C, the G-protein-coupled receptor kinases β ARK1, β ARK2, GRK1 and GRKs4-6,
25 calmodulin dependent kinase, polo, Akt/PKB and GSK3.

Specific examples of peptide derivatives of the present invention include peptides HJ-38 (SEQ ID NO.: 13), J-41 (SEQ ID NO.: 14), J-42 (SEQ ID NO.: 15), J-43 (SEQ ID NO.: 16), J-43.1 (SEQ ID NO.: 17), J-45 (SEQ ID
30 NO.: 18), J-46 (SEQ ID NO.: 19), J-47 (SEQ ID NO.: 20), J-48 (SEQ ID NO.: 21) and J-29 (SEQ ID NO.: 22), the sequences of which are shown in Figure 4. The N-terminus and/or C-terminus of these peptides can be modified, as described above. As indicated in Figure 4,
35 the N-terminal of these peptides is acetylated and the C-terminal is amidated. Other protecting groups for amides and carboxylic acids can be used, as described

above. Optionally, one or both protecting groups can be omitted. The peptides may be linear or cyclic.

Also included are peptides having the sequence of HJ-38 (SEQ ID NO.: 13), J-41 (SEQ ID NO.: 14), J-42 (SEQ ID NO.: 15), J-43 (SEQ ID NO.: 16), J-43.1 (SEQ ID NO.: 17), J-45 (SEQ ID NO.: 18), J-46 (SEQ ID NO.: 19), J-47 (SEQ ID NO.: 20), J-48 (SEQ ID NO.: 21) and J-29 (SEQ ID NO.: 22), with the proviso that any one of the amino residues in the peptide can vary, being any naturally occurring amino acid or analog thereof. The present invention also includes peptides having the sequence of with the proviso that any two of the amino residues in the peptide can vary, being any naturally occurring amino acid or analog thereof.

The present invention also includes cyclic peptides having amino acids sequences corresponding to a modified sequence or subsequence of the HJ loop of STKs and which modulate the activity of STKs.

A "cyclic peptide" refers, for example, to a peptide or peptide derivative in which a ring is formed by a peptide bond between the nitrogen atom at the N-terminus and the carbonyl carbon at the C-terminus.

"Cyclized" also refers to forming a ring by a covalent bond between the nitrogen at the N-terminus of the compound and the side chain of a suitable amino acid in the peptide, preferably the C-terminal amino acid. For example, an amide can be formed between the nitrogen atom at the N-terminus and the carbonyl carbon in the side chain of aspartic acid or glutamic acid.

Alternatively, the peptide or peptide derivative can be cyclized by forming a covalent bond between the carbonyl at the C-terminus of the compound and the side chain of a suitable amino acid in the peptide, preferably the N-terminal amino acid. For example, an amide can be formed between the carbonyl carbon at the C-terminus and the amino nitrogen atom in the side chain of lysine or ornithine; an ester can be formed between the carbonyl

carbon at the C-terminus and the hydroxyl oxygen atom in the side chain of serine or threonine.

"Cyclized" also refers to forming a ring by a covalent bond between the side chains of two suitable amino acids in the peptide, preferably the terminal amino acids. For example, a disulfide can be formed between the sulfur atoms in the side chains of two cysteines. Alternatively, an ester can be formed between the carbonyl carbon in the side chain of, for example, glutamic acid or aspartic acid, and the oxygen atom in the side chain of, for example, serine or threonine. An amide can be formed between the carbonyl carbon in the side chain of, for example, glutamic acid or aspartic acid, and the amino nitrogen in side chain of, for example, lysine or ornithine.

In addition, a peptide or peptide derivative can be cyclized with a linking group between the two termini, between one terminus and the side chain of an amino acid in the peptide or peptide derivative, or between the side chains to two amino acids in the peptide or peptide derivative. Suitable linking groups are disclosed in Lobl et al., WO 92/00995 and Chiang et al., WO 94/15958, the teachings of which are incorporated into this application by reference.

Suitable substitutions in the original amino acid sequence or subsequence are those which result in a peptide derivative, as defined above, which modulates the activity of a STK. The activity of a STK is "modulated" when the activity of the STK is increased or decreased. An increase or decrease in the activity of a STK can be detected by assessing in vitro the extent of phosphorylation of a protein substrate of the STK being tested or by a corresponding modulation, increase or decrease, in a cellular activity or function which is under the control of the STK. Examples of these cellular functions include cell proliferation, cell differentiation, cell morphology, cell survival or

apoptosis, cell response to external stimuli, gene expression, lipid metabolism, glycogen metabolism and mitosis.

It can be readily determined whether a peptide or peptide derivative modulates the activity of a STK by providing cells which have one or more cellular activities controlled by a STK. The cells are incubated with the peptide or peptide derivative to produce a test mixture under conditions suitable for assessing activity of the serine/threonine kinase. The activity of the STK is assessed and compared with a suitable control, e.g., the activity of the same cells incubated under the same conditions in the absence of the peptide or peptide derivative. A greater or lesser activity of the STK in the test mixture compared with the control indicates that the test peptide or peptide derivative modulates the activity of said STK.

Suitable cells for the assay include normal cells which express a membrane bound or intracellular STK, cells which have been genetically engineered to express a STK, malignant cells expressing a STK or immortalized cells which express a STK.

Conditions suitable for assessing STK activity include conditions suitable for assessing activity of a cellular activity or function under control of the STK. Generally, a cellular activity or function can be assessed when the cells are exposed to conditions suitable for cell growth, including a suitable temperature (for example, between about 30 °C to about 42 °C) and the presence of the suitable concentrations of nutrients in the medium (e.g., amino acids, vitamins, growth factors).

In another aspect, the activity of certain STK (e.g., Atk/PKB, Dudek et al., *Science* 275:661 (1997)) can be evaluated by growing the cells under serum deprivation conditions. Cells are typically grown in culture in the presence of a serum such as bovine serum,

horse serum or fetal calf serum. Many cells, for example, nerve cells such as PC-12 cells, generally do not survive when insufficient serum. The use of insufficient serum to culture cells is referred to as

5 "serum deprivation conditions" and includes, for example, from 0% to about 4% serum. STK activity is determined by the extent to which a peptide or peptide derivative can protect cells, e.g., neuronal cells, from the consequences of serum deprivation. Specific

10 conditions are provided in Dudek et al., and in Example 4 of co-pending and concurrently filed application entitled "SHORT PEPTIDES WHICH SELECTIVELY MODULATE INTRACELLULAR SIGNALLING" (filed on May 21, 1997, Attorney Docket No. CMCC-547), the teachings of which

15 are incorporated herein by reference.

Generally, the activity of the STK in the test mixture is assessed by making a quantitative measure of the cellular activity which the STK controls. The cellular activity can be, for example, cell

20 proliferation. Examples of cells in which proliferation is controlled by an STK include endothelial cells such as bovine aortic cells, mouse MSI cells or mouse SVR cells (see Arbiser et al., *Proc. Natl. Acad. Sci. USA* 94:861 (1997)), vascular smooth muscle cells, and

25 malignant cells of various tissues such as breast cancer, lung cancer, colon cancer, prostate cancer, melanoma). STK activity is assessed by measuring cellular proliferation, for example, by comparing the number cells present after a given period of time with

30 the number of cells originally present. STKs involved in cell proliferation are members of the polo family, Taf or Atk/PKB. If cells are being used in which the STK controls the cell differentiation (e.g., preadipocytes such as 3T3-L1 expressing STKs Akt/PKB,

35 GSK3 and protein kinase A - see Kohn et al., *J. Biol. Chem.* 271:31372 (1996)), activity is assessed by measuring the degree of differentiation. Activity can

be assessed by changes in the metabolic activity of cells such as primary adipocytes, hepatocytes and fibroblasts by measuring changes in glucose uptake, lipogenesis, or glycogen metabolism (see, for example, 5 Weise et al., *J. Biol. Chem.* 270:3442 (1995)). Activity can also be assessed by the extent to which the gene expression, cell morphology or cellular phenotype is altered (e.g., the degree to which cell shape is altered or the degree to which the cells assume a spindle-like 10 structure). One example of a change in cellular morphology is reported in the co-pending and concurrently filed application entitled "SHORT PEPTIDES WHICH SELECTIVELY MODULATE INTRACELLULAR SIGNALLING" (filed on May 21, 1997, Attorney Docket No. CMCC-547), 15 which discloses that certain peptide derivatives of the HJ loop of protein tyrosine kinases can cause vascular smooth muscle cells to become elongated and assume a spindle-like shape.

Specific examples of conditions suitable for 20 determining the activity of STKs by assessing cell proliferation are provided in Example 2.

It is to be understood that the assay described hereinabove for determining whether a peptide or peptide derivative modulates a cellular activity or function 25 under the control of a STK can be performed with cells other than those specifically described herein. STKs not yet discovered or STKs whose function is not yet known can also be used in this assay, once it has been determined which cellular functions or activities they 30 control. These STKs are also within the scope of the present invention.

The present invention is also directed to a method of modulating the activity of a serine/threonine kinase in a subject. A "subject" is preferably a human, but 35 can also be animals in need of treatment, e.g., veterinary animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses and the like) and

laboratory animals (e.g., rats, mice, guinea pigs and the like).

The activity of a STK in a subject can be modulated for the purpose of treating diseases which are caused by over activity or under activity of STKs. For example, MAP kinases (Seger and Krebs, *FASEB J.* 9:726 (1995)) and cyclin dependent protein kinases ("Molecular Biology of the Cell," Alberts, Bray, Lewis, Raff, Roberts and Watson, eds. Chapter 5, (Garland Publishing, Inc.), (1994)), are central components of the cell-division cycle control system in eukaryotic cells. Other STKs, for example, protein kinase C, Raf kinases (Nishizuka, *The FASEB Journal* 9:484 (1995), Locric, et al., *Oncogene* 12:1109 (1996) and Laird et al., *J. Biol. Chem.* 270:26,742 (1995)) and G protein-coupled receptors (Lange-Carter, et al., *Science* 260:315 (1993)), are, in turn, involved in the control of MAP kinases or are activated during mitosis. The G protein-coupled receptor kinases (GRKs), on the other hand, desensitize the receptors and are thereby involved in the regulation of various hormonal responses (Freedman and Lefkowitz, *Recent Prog. Hormon. Res.* 51:319 (1996). Activation of Akt/PKB is implicated in the inhibition of apoptosis, i.e., programmed cell death (Frank et al., *Cell* 88:435 (1997) and Hemmings *Science* 275:628 (1997)). Peptides and peptide derivatives of the present invention which modulate the activity of these enzymes can be used to treat cancer in a subject when administered to the subject in a therapeutically effective amount.

c-AMP dependent kinase, GSK3 and Akt/PKB are involved in the control of glycogen metabolism. Peptide and peptide derivatives of the present invention which modulate the activity of cAMP dependent kinase can be used to treat Type II diabetes and hemorrhagic shock in a subject when administered to the subject in a therapeutically effective amount. cAMP derivatives have also been reported to inhibit the growth of human cancer

cells (Katsros et al., *FEBS Lett.* 223:97 (1987)), indicating that inhibitors of cAMP dependent kinases can also be useful in the treatment of cancer.

Raf kinases are involved in the control of lipid metabolism. Peptide and peptide derivatives of the present invention which modulate the activity of Raf kinases can be used to treat obesity in a subject when administered to the subject in a therapeutically effective amount.

Agents which modulate the activity of protein kinase C can be used to treat a wide variety of disease conditions, including cardiovascular diseases (e.g., thrombosis, atherosclerosis, arteriosclerosis, cardiac hypertrophy, ischemia, reperfusion injury and hypertension), immunosuppressive and inflammatory disorders (e.g., asthma, psoriasis, systemic lupus erythematosus, diabetes mellitus, suppression of organ transplant rejection, multiple sclerosis, inflammatory bowel disease and AIDS), central nervous system diseases (e.g., Alzheimer's disease, stroke and trauma), septic shock based on protein kinase C activation and ischemia induced renal failure (Nambi, WO 93/16703, Bradshaw, et al., *Agents Action* 38:135 (1993) and Birchall et al., *The J. Pharm. and Exper. Therapeut.* 2:922 (1994)).

Peptide and peptide derivatives of the present invention which modulate the activity of protein kinase C can be used to treat these diseases in a subject when administered to the subject in a therapeutically effective amount.

Phosphorylation by G-protein receptor kinases are known (Freedman and Lefkowitz, *Recent Prog. Hormon. Res.* 51:319 (1996)) to result in receptor desensitization, thereby extending the duration of hormonal effects of, for example, adrenalin. Thus, agents which modulate the activity of G-protein receptor kinases have potential in the treatment of disease resulting from a lower bioavailability of the corresponding ligand, such

as dopamine. Inhibitors of calmodulin dependent kinases have been reported to inhibit dopamine release (Nagatsu et al., *Biochem. Biophys. Research, Commun.* 143:1045 (1987)). Thus, agents which modulate the activity of G-
5 protein receptor kinases and calmodulin receptor kinases are potentially useful in the treatment of diseases involving dysfunction of dopamine signalling, for example, Parkinson's Disease. Inhibitors of calmodulin dependent kinases have also been reported to relax
10 arterial muscle (Saitoh et al., *J. Bio. Chem.* 262:7796 (1987)) and therefore have potential in treating hypertension. Inhibition of GSK3 might increase the intracellular activity of the insulin receptor and thereby enhance glucose uptake and other related
15 metabolic activities. Thus, agents which modulate the activity of GSK3 are potentially useful in the treatment of Type I and Type II diabetes.

Based on methods disclosed herein, peptides and peptide derivatives can be designed to modulate the
20 activity of STKs whose HJ loop has been sequenced and whose cellular function is known. As a consequence, peptides and peptide derivatives can be designed to affect (increase or decrease) those cellular functions. It is possible that future research will reveal that
25 certain disease conditions, whose underlying causes are presently unknown, are brought about by the overactivity or underactivity of cellular functions controlled by STKs. These diseases can be treated by administering peptides which are peptide derivatives of the HJ loop of
30 the overactive or underactive STK. Suitable peptides and peptide derivatives can be identified by methods disclosed herein. These methods of treatment, peptides and peptide derivatives are encompassed within the scope of the present invention.

35 A "therapeutically effective amount" is the quantity of compound which results in an improved clinical outcome as a result of the treatment compared

with a typical clinical outcome in the absence of the treatment. An "improved clinical outcome" includes a longer life expectancy for individuals with the disease as a result of the treatment. An "improved clinical
5 outcome" can also result in the individual with the disease experiencing fewer symptoms or complications of the disease as a result of the treatment. With respect to cancer, an "improved clinical outcome" includes a longer life expectancy. It can also include slowing or
10 arresting the rate of growth of a tumor, causing a shrinkage in the size of the tumor, a decreased rate of metastasis and/or improved quality of life (e.g., a decrease in physical discomfort or an increase in mobility).

15 With respect to diabetes, an improved clinical outcome refers to a longer life expectancy, a reduction in the complications of the disease (e.g., neuropathy, retinopathy, nephropathy and degeneration of blood vessels) and an improved quality of life, as described
20 above.

With respect to obesity, an improved clinical outcome refers to increased weight reduction per calory intake. It also refers to a decrease in the complications which are a consequence of obesity, for
25 example heart disease such as arteriosclerosis and high blood pressure.

The amount of peptide or peptide derivative administered to the individual will depend on the type and severity of the disease and on the characteristics
30 of the individual, such as general health, age, sex, body weight and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Typically, a therapeutically effective amount of the peptide or
35 peptide derivative can range from about 1 mg per day to about 1000 mg per day for an adult. Preferably, the

dosage ranges from about 1 mg per day to about 100 mg per day.

The peptide and peptide derivatives of the present invention are preferably administered parenterally.

5 Parenteral administration can include, for example, systemic administration, such as by intramuscular, intravenous, subcutaneous, or intraperitoneal injection. Peptides or peptide derivatives which resist proteolysis can be administered orally, for example, in capsules,
10 suspensions or tablets.

The peptide or peptide derivative can be administered to the individual in conjunction with an acceptable pharmaceutical carrier as part of a pharmaceutical composition for treating the diseases
15 discussed above. Suitable pharmaceutical carriers may contain inert ingredients which do not interact with the peptide or peptide derivative. Standard pharmaceutical formulation techniques may be employed such as those described in Remington's Pharmaceutical Sciences, Mack
20 Publishing Company, Easton, PA. Suitable pharmaceutical carriers for parenteral administration include, for example, sterile water, physiological saline, bacteriostatic saline (saline containing about 0.9% mg/ml benzyl alcohol), phosphate-buffered saline, Hank's
25 solution, Ringer's-lactate and the like. Methods for encapsulating compositions (such as in a coating of hard gelatin or cyclodextran) are known in the art (Baker, et al., *Controlled Release of Biological Active Agents*, John Wiley and Sons, 1986).

30 The peptide and peptide derivatives of the present invention have many utilities other than for therapy. Some of these uses are discussed in the following paragraphs.

The HJ loop peptides of the present invention are
35 derived from an array which is linear in the native protein. Therefore, they can be useful in the preparation of specific antibodies against STKs.

Moreover, since the HJ-loop sequence is unique to each sub-family of STK, anti-HJ-loop antibodies can be specifically used to isolate distinct sub-families of STK.

5 Suitable antibodies can be raised against an HJ loop peptide by conjugating to a suitable carrier, such as keyhole limpet hemocyanin or serum albumin; polyclonal and monoclonal antibody production can be performed using any suitable technique. A variety of
10 methods have been described (see e.g., Kohler et al., *Nature*, 256: 495-497 (1975) and *Eur. J. Immunol.* 6: 511-519 (1976); Milstein et al., *Nature* 266: 550-552 (1977); Koprowski et al., U.S. Patent No. 4,172,124; Harlow, E. and D. Lane, 1988, *Antibodies: A Laboratory Manual*,
15 (Cold Spring Harbor Laboratory: Cold Spring Harbor, NY); *Current Protocols In Molecular Biology*, Vol. 2 (Supplement 27, Summer 1994), Ausubel, F.M. et al., Eds., (John Wiley & Sons: New York, NY), Chapter 11, (1991)). Generally, a hybridoma can be produced by
20 fusing a suitable immortal cell line (e.g., a myeloma cell line such as SP2/0) with antibody producing cells. The antibody producing cell, preferably those of the spleen or lymph nodes, can be obtained from animals immunized with the antigen of interest. The fused cells
25 (hybridomas) can be isolated using selective culture conditions, and cloned by limiting dilution. Cells which produce antibodies with the desired specificity can be selected by a suitable assay (e.g., ELISA).

Antibodies, including monoclonal antibodies,
30 against HJ loop peptides have a variety of uses. For example, those against or reactive with the protein from which the HJ peptides was derived, and preferably which bind specifically to said protein, can be used to identify and/or sort cells exhibiting that protein on
35 the cell surface (e.g., by means of fluorescence activated cell sorting or histological analyses). Monoclonal antibodies specific for the protein can also

be used to detect and/or quantitate the protein expressed on the surface of a cell or present in a sample (e.g., in an ELISA). Alternatively, the antibodies can be used to determine if an intracellular
5 STK is present in the cytoplasm of the cell. A cleared lysate of the cell is generated (for example, by treating the cells with sodium hydroxide (0.2 N) and sodium dodecyl sulfate (1%), centrifugating and separating the supernatant from the pellet), and treated
10 with anti-HJ loop antibody specific for the STK. The cleared lysate is then analyzed, for example, by Western blotting or immunoprecipitation for complexes between STK and antibody. Some STKs become membrane-bound or cytoskeleton-associated following stimulation. Anti-HJ-
15 loop antibodies can be utilized for the study of the intracellular distribution (compartmentalization) of various subfamilies of STKs under various physiological conditions via the application of conventional immunocytochemistry such as immunofluorescence,
20 immunoperoxidase technique and immunoelectron microscopy, in conjunction with the specific anti-HJ-loop antibody.

Antibodies reactive with the immunogen are also useful. For example, they can be used to detect and/or
25 quantitate immunogen in a sample, or to purify immunogen (e.g., by immunoaffinity purification).

The HJ loop within STKs plays a key role in regulating the activity of STKs, as is evidenced by the fact that the peptides and peptide derivatives of the
30 present invention have such a dramatic effect on the activity of STKs. The HJ loop peptides of the present invention can also be used to identify ligands which interact with the HJ-loops of specific STKs and which modulate the activity STKs. For example, an affinity
35 column can be prepared to which a specific HJ-loop is covalently attached, directly or via a linker. This column, in turn, can be utilized for the isolation and

identification of specific ligands which bind the HJ loop peptide and which will also likely bind the STK from which the HJ loop peptide was derived. The ligand can then be eluted from the column, characterized and
5 tested for its ability modulate STK function.

Protein tyrosine kinases are another class of protein kinases. These proteins occur as membrane-bound receptors, which participate in transmembrane signaling, or as intracellular proteins which take part in signal
10 transduction within the cell, including signal transduction to the nucleus. Binding of a ligand results in signal transduction, initiated by the phosphorylation of tyrosine residues of intracellular proteins by the kinase. As with STKs, tyrosine kinases
15 control cellular functions by means of this phosphorylation mechanism. Tyrosine kinases have a high degree of homology with STKs, including an HJ loop. Consequently, the activity of tyrosine kinases and the cellular functions which they control, can be modulated
20 with peptides which are peptide derivatives of their HJ loops, as discussed above for STKs. Peptides and peptide derivatives of the HJ loop of protein tyrosine kinases and methods of use thereof are disclosed in the co-pending and concurrently filed application entitled
25 "SHORT PEPTIDES WHICH SELECTIVELY MODULATE INTRACELLULAR SIGNALLING" (Attorney Docket No. CMCC-547, filed May 21, 1997), the teachings of which are incorporated into this application.

Peptide sequences in the compounds of the present
30 invention may be synthesized by solid phase peptide synthesis (e.g., BOC or FMOC) method, by solution phase synthesis, or by other suitable techniques including combinations of the foregoing methods. The BOC and FMOC methods, which are established and widely used, are
35 described in Merrifield, *J. Am. Chem. Soc.* 88:2149 (1963); Meienhofer, *Hormonal Proteins and Peptides*, C.H. Li, Ed., Academic Press, 1983, pp. 48-267; and Barany

and Merrifield, in *The Peptides*, E. Gross and J. Meienhofer, Eds., Academic Press, New York, 1980, pp. 3-285. Methods of solid phase peptide synthesis are described in Merrifield, R.B., *Science*, 232: 341 (1986);
5 Carpino, L.A. and Han, G.Y., *J. Org. Chem.*, 37: 3404 (1972); and Gauspohl, H. et al., *Synthesis*, 5: 315 (1992)). The teachings of these references are incorporated herein by reference.

Methods of cyclizing compounds having peptide
10 sequences are described, for example, in Lobl et al., WO 92/00995, the teachings of which are incorporated herein by reference. Cyclized compounds can be prepared by protecting the side chains of the two amino acids to be used in the ring closure with groups that can be
15 selectively removed while all other side-chain protecting groups remain intact. Selective deprotection is best achieved by using orthogonal side-chain protection such as allyl (OAI) (for the carboxyl group in the side chain of glutamic acid or aspartic acid, for
20 example), allyloxy carbonyl (Aloc) (for the amino nitrogen in the side chain of lysine or ornithine, for example) or acetamidomethyl (Acm) (for the sulfhydryl of cysteine) protecting groups. OAI and Aloc are easily removed by Pd⁰ and Acm is easily removed by iodine
25 treatment.

The invention is illustrated by the following examples which are not intended to be limiting in any way.

Example 1 - Preparation of HJ Peptides

30 The novel compounds of this invention can be synthesized utilizing a 430A Peptide Synthesizer from Applied Biosystems using F-Moc technology according to manufacturer's protocols. Other suitable methodologies for preparing peptides are known to person skilled in
35 the art. See e.g., Merrifield, R.B., *Science*, 232: 341 (1986); Carpino, L.A., Han, G.Y., *J. Org. Chem.*, 37:

3404 (1972); Gauspohl, H., et al., *Synthesis*, 5: 315 (1992)), the teachings of which are incorporated herein by reference.

Rink Amide Resin [4(2',4' Dimethoxyphenyl-FMOC amino methyl) phenoxy resin] was used for the synthesis of C-amidated peptides. The alpha-amino group of the amino acid was protected by an FMOC group, which was removed at the beginning of each cycle by a weak base, 20% piperidine in N-methylpyrrolidone (NMP). After deprotection, the resin was washed with NMP to remove the piperidine. *In situ* activation of the amino acid derivative was performed by the FASTMOC Chemistry using HBTU (2(1-benzotriazolyl-1-yl)-1,1,3,3-tetramethyluronium) dissolved in HOBt (1-hydroxybenzotriazole) and DMF (dimethylformamide). The amino acid was dissolved in this solution with additional NMP. DIEA (diisopropylethylamine) was added to initiate activation. Alternatively, the activation method of DCC (dicyclohexylcarbodiimide) and HOBt was utilized to form an HOBt active ester. Coupling was performed in NMP. Following acetylation of the N-terminus (optional), TFA (trifluoroacetic acid) cleavage procedure of the peptide from the resin and the side chain protecting groups was applied using 0.75 g crystalline phenol; 0.25 ml EDT (1,2-ethanedithiol); 0.5 ml thioanisole; 0.5 ml D.I. H₂O; 10 ml TFA.

Example 2 - HJ Peptide Derivatives of Raf and Polo
Modulate Proliferation of Endothelial
Cells *In Vitro*

Bovine aortic cells (referred to herein as "A19 cells") were obtained by the procedure disclosed in Gospodorowicz et al., *Proc. Natl. Acad. Sci.* 73:4120 (1976)). Mouse MS1 and SVR cells were obtained by the procedures disclosed in Arbiser et al., *Proc. Natl. Acad. Sci.* 94:861 (1997), the teachings of which are incorporated herein by reference.

96 well, flat bottom, tissue culture microtiter plates were precoated with gelatin (Difco) immediately prior to cell plating by adding 0.100 ml/well of freshly filtered 1% gelatin in glass double distilled water (DDW). The wells were incubated for about 1 hour at 37°C, and then the excess solution was removed by aspiration.

Culture medium was prepared from DMEM, penicillin/streptomycin/glutamine (penicillin - 100 U/ml; streptomycin - 100 µg/mL; and glutamine - 2mM) and 10% endotoxin free bovine calf serum (Hyclone). A suspension of the cell type being tested at 25×10^3 cells/ml was prepared in the above described culture medium and distributed 0.160 ml/well (about 4000 endothelial cells/well).

A series of HJ peptide stock solutions was prepared by diluting a 10 mM solution of the HJ peptide in 100% DMSO with phosphate buffered saline (PBS) containing 0.1% BSA. The concentration of HJ peptide in each stock solution was adjusted to nine times the desired concentration of the HJ peptide in the assay mixture.

0.020 ml of each HJ peptide stock solution was added to the corresponding wells about 2 hours after cell plating, with six replicates for each concentration. In addition, BSA solution with no added HJ peptide was used as a control. The wells were incubated for 72-80 hours at 37°C in a 10% CO₂ humidified incubator.

The plates were labeled and the medium discarded. Each plate was then washed one time with PBS (0.200 ml/well). The wells were then fixed by washing with 100% ethanol (0.200 ml/well for 5 minutes). The ethanol was removed and the wells dried completely. Alternatively, the wells were fixed with 4% formaldehyde PBS (PBS buffered 10% formalin from Fisher Scientific; Catalog No. HC200-1) (0.12 ml/well) for at least 30

minutes. Fixing with formaldehyde enhances the O.D. compared with ethanol.

The wells were washed one time with borate buffer (0.1 M, pH 8.5). Freshly filtered 1% methylene blue solution (0.600 ml/well) was then added to the wells and incubated for 10 minutes at room temperature. The wells were then washed five times with tap water, after which the wells were dried completely. 0.200 ml/well of 0.1 N HCl (0.1 N) was added to extract the color. After extracting overnight, the O.D. was read at 630 nm to determine the number of cells per well. The procedure for counting cells is described in greater detail in Oliver et al., *J. of Cell Sci.*, 92:513 (1989), the teachings of which are incorporated herein by reference.

The results for a number of different HJ peptides are shown in the Table.

Table

	Peptide	S.I.* (μ M) for SVR Cells	S.I.* (μ M) for MS1 Cells	S.I.* (μ M) for A19 Cells
	HJ38	10	10	Not Tested
5	J41	Not Tested	10	Not Tested
	J42	10	Not Tested	10
	J43	Not Tested	Not Tested	40

*Concentration at which significant inhibition of cell proliferation was observed.

10 As can be can from the results in the Table, HJ peptide derivatives of Raf and Polo inhibited cell proliferation of bovine aortic cells and the transformed mouse cell lines MS1 and SVR.

Example 3 - The HJ Peptide Derivative of
 15 Activin/TGFbR KO48H101 (SEQ ID NO.: 24)
 Inhibits the Production of Collagen by
 Fetal Lung Fibroblasts
 Cells

Fetal lungs fibroblasts are suspended in DMEM
 20 medium containing 0.5% FCS and seeded in a 96-well flat
 bottom tissue culture plate at a density of 50,000 cells
 per well (45 μ l per well). The cells are incubated for
 48 hours in the presence of 45 μ l of heat activated
 TGF β -containing condition medium (collected from MCF-7
 25 cells), and in the absence or presence of increasing
 concentrations of the tested peptide (0-10 μ M in 10 μ l PBS
 + 0.1% BSA + 1% DMSO). The total volume is 100 μ l per
 well.

Soluble Collagen

At the end of the incubation period, supernatants are removed and plated in 50 μ l per well aliquots into a new tissue culture plate. The plate is incubated at 5 37°C for 24 hours in a humid atmosphere to allow collagen adhesion then dried at 37°C for 24 hours. The dry plate is washed 3 times with distilled water, 200 μ l per well and 1 minute per wash and stained with 100 μ l of 0.1% direct red 80 in saturated picric acid (w/v) per 10 well, for 1 hour at room temperature. Excess dye is removed by washing the wells 5 times with 10mM HCl, 200 μ l per well and 10 sec per wash. Collagen-bound stain is eluted with 200 μ l of 0.1M NaOH per well, and read at 540nm.

15 Cell Count

Subsequent to the supernatant removal, the cells are fixed with 200 μ l buffered formaline per well, for 1 hour at room temperature and then washed with 200 μ l of 0.1M borate buffer per well. The fixed cells are 20 stained with 50 μ l of 1% methylene blue per well, for 15 minutes at room temperature. Excess dye is washed with tap water. Cell-bound dye is eluted with 200 μ l of 0.1M HCl per well, and read at 595nm. Collagen is expressed per cell.

25 The results for KO48H101 (SEQ ID NO.: 24) are shown in Figure 5. As can be seen from Figure 5, nearly complete inhibition of collagen production occurs at concentrations as low as 1 μ M of KO48H101. About 80% inhibition occurs in the presence of about 0.6 μ M 30 KO48H101.

The inhibition of collagen-formation might be useful for the inhibition of scar-formation, e.g. in plastic surgery and for the inhibition of adhesion-formation, a major complication of abdominal 35 surgery.

Example 4 - The HJ Peptide Derivative of Integrin-Linked Kinase (ILK) K107H101 (SEQ ID NO.: 47) Causes Morphological Changes in B16 Melanoma Cells

5 A change of morphology of B16 melanoma cells was observed when incubated in the presence of K107H101, a peptide derived from the HJ-loop of the serine/threonine kinase named integrin-linked kinase (ILK). As described in Wu C. et al., J. Bio. Cem. 273:528-536 (1998)), ILK
10 is implicated in tumor formation. Therefore, ILK-derived peptides might be useful as anti-tumor agents. The entire teachings of Wu et al., are incorporated herein by reference.

EQUIVALENTS

15 Those skilled in the art will be able to recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the
20 following claims.

CLAIMS

What is claimed is:

1. A peptide comprising a peptide derivative of the HJ loop of a serine/threonine kinase, wherein:
 - 5 a) said peptide has between about five and about twenty amino acids or amino acid analogs; and
 - b) said peptide modulates activity of the serine/threonine kinase.
- 10 2. The peptide of Claim 1 wherein the peptide is cyclic.
3. The peptide of Claim 1 wherein the peptide is linear.
4. The peptide of Claim 3 wherein the N-terminus and the C-terminus of the peptide are unsubstituted.
- 15 5. The peptide of Claim 3 wherein at least one of the N-terminus or the C-terminus is substituted.
6. The peptide of Claim 5 wherein the N-terminus is amidated and the C-terminus is acylated.
- 20 7. The peptide of Claim 3 wherein the peptide derivative has an amino acid sequence corresponding to any subsequence of the amino acid sequence of said HJ loop of said serine/threonine kinase, with the proviso that any one amino acid in the sequence of the peptide derivative can vary, being any amino acid or analog thereof.
- 25 8. The peptide of Claim 3 wherein the serine/threonine kinase is member of a serine/threonine kinase

family selected from the group of families consisting of polo, Raf, mitogen-activated protein kinases (MAP kinases) and G protein-coupled receptor kinases.

- 5 9. The peptide of Claim 3 wherein the serine/threonine kinase is selected from the group consisting of protein kinase C, cyclic AMP dependent kinase, calmodulin dependent kinase, cyclic GMP dependent protein kinase, Akt/PKB and GSK3.
- 10 10. The peptide of Claim 8 wherein the serine/threonine kinase is a member of the polo family and is selected from the group consisting of Plk, Snk and Sak.
- 15 11. The peptide of Claim 8 wherein the serine/threonine kinase is from the Raf family and is selected from the group consisting of Raf-1, A-Raf and B-Raf.
- 20 12. The peptide of Claim 8 wherein the serine/threonine kinase is a G-protein dependent kinases selected from the group consisting of β 2-adrenergic receptor kinases, rhodopsin kinase and GRK4-6.
13. The peptide of Claim 3 wherein the peptide derivative has an amino acid sequence corresponding to any subsequence of the amino acid sequence of said HJ loop.
- 25 14. The peptide of Claim 3 wherein the peptide has the sequence of HJ-38 (SEQ ID NO.: 13), J-41 (SEQ ID NO.: 14), J-42 (SEQ ID NO.: 15), J-43 (SEQ ID NO.: 16), J-43.1 (SEQ ID NO.: 17), J-45 (SEQ ID NO.: 18), J-46 (SEQ ID NO.: 19), J-47 (SEQ ID NO.: 20), J-48 (SEQ ID NO.: 21) or J-29 (SEQ ID NO.: 22).
- 30

15. A peptide having the sequence of HJ-38 (SEQ ID NO.: 13), J-41 (SEQ ID NO.: 14), J-42 (SEQ ID NO.: 15), J-43 (SEQ ID NO.: 16₋), J-43.1 (SEQ ID NO.: 17), J-45 (SEQ ID NO.: 18), J-46 (SEQ ID NO.: 19), J-47 (SEQ ID NO.: 20), J-48 (SEQ ID NO.: 21) or J-29 (SEQ ID NO.: 22), with the proviso that any one amino acid residue in the peptide can vary, being any naturally occurring amino acid or analog thereof.
- 10 16. A peptide comprising a sequence of amino acids AA₁ through AA₂₀ or a subsequence thereof comprising at least five amino acids, wherein:
- AA₁ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;
- 15 AA₂ is selected from the group consisting of glutamine, asparagine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;
- 20 AA₃ is selected from the group consisting of leucine, isoleucine, methionine and valine;
- AA₄ is selected from the group consisting of leucine, isoleucine, methionine and valine;
- 25 AA₅ is selected from the group consisting of alanine, serine and threonine;
- AA₆ is glycine or alanine;
- AA₇ is selected from the group consisting of glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;
- 30 AA₈ is selected from the group consisting of leucine, isoleucine, methionine and valine;
- AA₉ is proline;
- 35 AA₁₀ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;

AA₁₁ is selected from the group consisting of alanine, serine and threonine;

5 AA₁₂ is selected from the group consisting of histidine, asparagine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

AA₁₃ is selected from the group consisting of leucine, isoleucine, methionine and valine;

10 AA₁₄ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

15 AA₁₅ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

20 AA₁₆ is selected from the group consisting of arginine, N-nitroarginine, β -cycloarginine, γ -hydroxyarginine, N-amidinocitruline and 2-amino-4-guanidinobutanoic acid;

25 AA₁₇ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

30 AA₁₈ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

35 AA₁₉ is selected from the group consisting of leucine, isoleucine, methionine and valine; and

AA₂₀ is selected from the group consisting of leucine, isoleucine, methionine and valine.

17. The peptide of Claim 16 wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to the sequence of the HJ loop of Raf (SEQ ID NO.: 1) or a subsequence thereof, with the proviso that any two amino acids in the sequence AA₁ through AA₂₀ or the subsequence thereof can vary.
18. The peptide of Claim 16 wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to the sequence or a subsequence of the HJ loop of Raf (SEQ ID NO.: 1), with the proviso that any one amino acid in the sequence AA₁ through AA₂₀ or the subsequence thereof can vary.
19. The peptide of Claim 18 or Claim 20 wherein the peptide comprises an eight amino acid subsequence of the sequence AA₁ through AA₂₀, wherein the subsequence is selected from the group consisting of AA₃ through AA₁₀, AA₇ through AA₁₄ and AA₁₁ through AA₁₈.
20. A peptide comprising a sequence of amino acids AA₁ through AA₂₀ or a subsequence thereof comprising at least five amino acids, wherein:
- AA₁ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;
- AA₂ is selected from the group consisting of glutamine, asparagine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;
- AA₃ is selected from the group consisting of leucine, isoleucine, methionine and valine;
- AA₄ is alanine or glycine;
- AA₅ is selected from the group consisting of alanine, leucine, isoleucine, methionine and valine;

AA₆ is glycine or alanine;

AA₇ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;

AA₈ is proline;

5 AA₉ is proline;

AA₁₀ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;

AA₁₁ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;

10 AA₁₂ is glycine or alanine;

AA₁₃ is selected from the group consisting of glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

15 AA₁₄ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

20 AA₁₅ is proline;

AA₁₆ is selected from the group consisting of leucine, isoleucine, methionine and valine;

25 AA₁₇ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

30 AA₁₈ is selected from the group consisting of leucine, isoleucine, methionine and valine;

AA₁₉ is selected from the group consisting of tyrosine, phenylalanine and tryptophan; and

35 AA₂₀ is selected from the group consisting of glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid.

21. The peptide of Claim 20 wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to the sequence of the HJ loop of cyclic AMP dependent kinase (SEQ ID NO.: 2) or a subsequence thereof, with the proviso that any two amino acids in the sequence AA₁ through AA₂₀ or the subsequence thereof can vary.
22. The peptide of Claim 20 wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to the sequence or a subsequence of the HJ loop of cyclic AMP dependent kinase (SEQ ID NO.: 2), with the proviso that any one amino acid in the sequence AA₁ through AA₂₀ or the subsequence thereof can vary.
23. The peptide of Claim 21 or Claim 22 wherein the peptide comprises an eight amino acid subsequence of the sequence A₁ through AA₂₀, wherein the subsequence is selected from the group consisting of AA₃ through AA₁₀, AA₇ through AA₁₄ and AA₁₁ through AA₁₈.
24. A peptide comprising a sequence of amino acids AA₁ through AA₂₀ or a subsequence thereof comprising at least five amino acids, wherein:
- AA₁ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;
- AA₂ is selected from the group consisting of glutamine, asparagine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;
- AA₃ is selected from the group consisting of leucine, isoleucine, methionine and valine;
- AA₄ is selected from the group consisting of leucine, isoleucine, methionine and valine;

AA₅ is selected from the group consisting of cysteine, alanine, leucine, isoleucine, methionine and valine;

AA₆ is glycine or alanine;

5 AA₇ is selected from the group consisting of histidine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

10 AA₈ is selected from the group consisting of proline, alanine and serine;

AA₉ is proline;

AA₁₀ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;

15 AA₁₁ is selected from the group consisting of histidine, glutamine, asparagine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

20 AA₁₂ is glycine or alanine;

25 AA₁₃ is selected from the group consisting of glutamine, asparagine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

30 AA₁₄ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

35 AA₁₅ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

AA₁₆ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

AA₁₇ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

AA₁₈ is selected from the group consisting of leucine, isoleucine, methionine and valine;

AA₁₉ is selected from the group consisting of tyrosine, phenylalanine and tryptophan; and

AA₂₀ is selected from the group consisting of histidine glutamic acid, and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid.

25. The peptide of Claim 24 wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to the sequence of the HJ loop of protein kinase C (SEQ ID NO.: 3) or a subsequence thereof, with the proviso that any two amino acids in the sequence AA₁ through AA₂₀ or the subsequence thereof can vary.

26. The peptide of Claim 24 wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to a sequence or a subsequence of the HJ loop of protein kinase C (SEQ ID NO.: 3), with the proviso that any one amino acid in the sequence AA₁ through AA₂₀ or the subsequence thereof can vary.

27. The peptide of Claim 25 or Claim 26 wherein the peptide comprises an eight amino acid subsequence of the sequence A₁ through AA₂₀, wherein the

subsequence is selected from the group consisting of AA₃ through AA₁₀, AA₇ through AA₁₄ and AA₁₁ through AA₁₈.

28. A peptide comprising a sequence of amino acids AA₁ through AA₂₀ or a subsequence thereof comprising at least five amino acids, wherein:
- AA₁ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;
- AA₂ is lysine or ornithine;
- AA₃ is selected from the group consisting of leucine, isoleucine, methionine and valine;
- AA₄ is selected from the group consisting of leucine, isoleucine, methionine and valine;
- AA₅ is selected from the group consisting of arginine, N-nitroarginine, β -cycloarginine, γ -hydroxyarginine, amidinocitruline and 2-amino-4-guanidinobutanoic acid;
- AA₆ is glycine or alanine;
- AA₇ is histidine;
- AA₈ is serine or threonine;
- AA₉ is proline;
- AA₁₀ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;
- AA₁₁ is selected from the group consisting of arginine, N-nitroarginine, β -cycloarginine, γ -hydroxyarginine, amidinocitruline and 2-amino-4-guanidinobutanoic acid;
- AA₁₂ is selected from the group consisting of glutamine, asparagine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;
- AA₁₃ is histidine;
- AA₁₄ is lysine or ornithine;
- AA₁₅ is serine or threonine;
- AA₁₆ is lysine or ornithine;

AA₁₇ is selected from the group consisting of glutamine, asparagine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

AA₁₈ is lysine or ornithine;

AA₁₉ is histidine; and

AA₂₀ is selected from the group consisting of glutamine, asparagine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid.

29. The peptide of Claim 28 wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to the sequence of the HJ loop of bARK1.2 (SEQ ID NO.: 4) or a subsequence thereof, with the proviso that any two amino acids in the sequence AA₁ through AA₂₀ or the subsequence thereof can vary.

30. The peptide of Claim 28 wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to the sequence or a subsequence of the HJ loop of bARK1.2 (SEQ ID NO.: 4), with the proviso that any one amino acid in the sequence AA₁ through AA₂₀ or the subsequence thereof can vary.

31. The peptide of Claim 29 or Claim 30 wherein the peptide comprises an eight amino acid subsequence of the sequence A₁ through AA₂₀, wherein the subsequence is selected from the group consisting of AA₃ through AA₁₀, AA₇ through AA₁₄ and AA₁₁ through AA₁₈.

32. A peptide comprising a sequence of amino acids AA₁ through AA₂₀ or a subsequence thereof comprising at least five amino acids, wherein:

AA₁ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;

5 AA₂ is selected from the group consisting of glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

AA₃ is selected from the group consisting of leucine, isoleucine, methionine and valine;

10 AA₄ is selected from the group consisting of leucine, isoleucine, methionine and valine;

AA₅ is selected from the group consisting of cysteine, serine and threonine;

AA₆ is glycine or alanine;

15 AA₇ is selected from the group consisting of arginine, N-nitroarginine, β -cycloarginine, γ -hydroxyarginine, N-amidinocitruline and 2-amino-4-guanidinobutanoic;

20 AA₈ is selected from the group consisting of leucine, isoleucine, methionine and valine;

AA₉ is proline;

AA₁₀ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;

25 AA₁₁ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;

AA₁₂ is asparagine or glutamine;

AA₁₃ is asparagine or glutamine;

30 AA₁₄ is selected from the group consisting of asparatic acid, glutamic acid and an aliphatic, substituted aliphatic, aromatic, substituted aromatic acid, benzylic or substituted benzylic ester of aspartic acid or glutamic acid;

AA₁₅ is selected from the group consisting of lysine, ornithine and histidine;

35 AA₁₆ is selected from the group consisting of asparatic acid, glutamic acid and an aliphatic, substituted aliphatic, aromatic, substituted

aromatic acid, benzylic or substituted benzylic ester of aspartic acid or glutamic acid;

5 AA₁₇ is selected from the group consisting of arginine, N-nitroarginine, β-cycloarginine, γ-hydroxyarginine, N-amidinocitruline, 2-amino-4-guanidinobutanoic, lysine and ornithine;

 AA₁₈ is selected from the group consisting of leucine, isoleucine, methionine and valine;

10 AA₁₉ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;

 AA₂₀ is selected from the group consisting of asparatic acid, glutamic acid and an aliphatic, substituted aliphatic, aromatic, substituted aromatic acid, benzylic or substituted benzylic ester of aspartic acid or glutamic acid.

15

33. The peptide of Claim 32 wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to the sequence of the HJ loop of Akt/PKB (SEQ ID NO.: 7) or a subsequence thereof, with the proviso that any two amino acids in the sequence AA₁ through AA₂₀ or the subsequence thereof can vary.

20

34. The peptide of Claim 32 wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to the sequence or a subsequence of the HJ loop of Akt/PKB (SEQ ID NO.: 7), with the proviso that any one amino acid in the sequence AA₁ through AA₂₀ or the subsequence thereof can vary.

25

35. The peptide of Claim 33 or Claim 34 wherein the peptide comprises an eight amino acid subsequence of the sequence A₁ through AA₂₀, wherein the subsequence is selected from the group consisting of AA₃ through AA₁₀, AA₇ through AA₁₄ and AA₁₁ through AA₁₈.

30

36. A peptide comprising a sequence of amino acids AA₁ through AA₂₀, or a subsequence thereof comprising at least five amino acids, wherein:

5 AA₁ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;

AA₂ is selected from the group consisting of leucine, isoleucine, methionine and valine;

AA₃ is selected from the group consisting of leucine, isoleucine, methionine and valine;

10 AA₄ is selected from the group consisting of leucine, isoleucine, methionine and valine;

AA₅ is selected from the group consisting of glutamine, leucine, isoleucine, methionine and valine;

15 AA₆ is glycine or alanine;

AA₇ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;

AA₈ is proline;

AA₉ is proline;

20 AA₁₀ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;

AA₁₁ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;

25 AA₁₂ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

30 AA₁₃ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

35 AA₁₄ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl,

substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

5 AA₁₅ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

AA₁₆ is histidine;

10 AA₁₇ is selected from the group consisting of arginine, N-nitroarginine, β -cycloarginine, γ -hydroxyarginine, amidinocitruline, 2-amino-4-guanidinobutanoic acid lysine and ornithine;

15 AA₁₈ is selected from the group consisting of lysine, ornithine, leucine, isoleucine, methionine and valine;

AA₁₉ is selected from the group consisting of tyrosine, phenylalanine and tryptophan; and

20 AA₂₀ is selected from the group consisting of glutamine, asparagine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid.

25 37. The peptide of Claim 36 wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to the sequence of the HJ loop of calmodulin dependent kinase (SEQ ID NO.: 5) or a subsequence thereof, with the proviso that any two amino acids in the sequence AA₁ through AA₂₀ or the subsequence thereof can vary.

30 38. The peptide of Claim 36 wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to the sequence or a subsequence of the HJ loop of calmodulin dependent kinase (SEQ ID NO.: 5), with the proviso that any one amino acid in the sequence
35 AA₁ through AA₂₀ or the subsequence thereof can vary.

39. The peptide of Claim 37 or Claim 38 wherein the peptide comprises an eight amino acid subsequence of the sequence A₁ through AA₂₀, wherein the subsequence is selected from the group consisting of AA₃ through AA₁₀, AA₇ through AA₁₄ and AA₁₁ through AA₁₈.
40. A peptide comprising a sequence of amino acids AA₁ through AA₂₀ or a subsequence thereof comprising at least five amino acids, wherein:
- AA₁ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;
- AA₂ is selected from the group consisting of serine and threonine;
- AA₃ is selected from the group consisting of leucine, isoleucine, methionine and valine;
- AA₄ is selected from the group consisting of leucine, isoleucine, methionine and valine;
- AA₅ is selected from the group consisting of leucine, isoleucine, methionine and valine;
- AA₆ is glycine or alanine;
- AA₇ is selected from the group consisting of arginine, N-nitroarginine, β -cycloarginine, γ -hydroxyarginine, amidinocitruline, 2-amino-4-guanidinobutanoic acid lysine and ornithine;
- AA₈ is proline;
- AA₉ is proline;
- AA₁₀ is selected from the group consisting of tyrosine, phenylalanine and tryptophan;
- AA₁₁ is selected from the group consisting of asparagine, glutamine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;
- AA₁₂ is serine or threonine;
- AA₁₃ is serine or threonine;
- AA₁₄ is selected from the group consisting of cysteine, serine and threonine;

AA₁₅ is selected from the group consisting of leucine, isoleucine, methionine and valine;

AA₁₆ is lysine or ornithine;

5 AA₁₇ is selected from the group consisting of glutamine, asparagine, glutamic acid, aspartic acid and an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic ester of glutamic acid or aspartic acid;

AA₁₈ is serine or threonine;

10 AA₁₉ is selected from the group consisting of tyrosine, phenylalanine and tryptophan; and

AA₂₀ is selected from the group consisting of leucine, isoleucine, methionine and valine.

41. The peptide of Claim 40 wherein the sequence AA₁
15 through AA₂₀ or the subsequence thereof corresponds to the sequence of the HJ loop of polo (SEQ ID NO.: 6) or a subsequence thereof, with the proviso that any two amino acids in the sequence AA₁ through AA₂₀ or the subsequence thereof can vary.

20 42. The peptide of Claim 40 wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to the sequence or a subsequence of the HJ loop of polo (SEQ ID NO.: 6), with the proviso that any one amino acid in the sequence AA₁ through AA₂₀ or the
25 subsequence thereof can vary.

43. The peptide of Claim 41 or Claim 42, wherein the peptide comprises an eight amino acid subsequence of the sequence A₁ through AA₂₀, wherein the subsequence is selected from the group consisting of AA₃ through
30 AA₁₀, AA₇ through AA₁₄ and AA₁₁ through AA₁₈.

44. A peptide comprising a sequence of amino acid residues AA₁ through AA₂₀ or a subsequence thereof

comprising at least five amino acid residues,
wherein:

AA₁ is alanine or glycine;

5 AA₂ is glutamic acid, aspartic acid or an
aliphatic, substituted aliphatic, benzyl,
substituted benzyl, aromatic or substituted aromatic
ester of glutamic acid or aspartic acid;

AA₃ is leucine, isoleucine, methionine or
valine;

10 AA₄ is leucine, isoleucine, methionine or
valine;

AA₅ is leucine, isoleucine, methionine or
valine;

AA₆ is glycine or alanine;

15 AA₇ is asparagine or glutamine;

AA₈ is proline;

AA₉ is leucine, isoleucine, methionine or
valine;

AA₁₀ is tyrosine, phenylalanine and tryptophan;

20 AA₁₁ is proline;

AA₁₂ is glycine or alanine;

25 AA₁₃ is aspartic acid, glutamic acid or an
aliphatic, substituted aliphatic, benzyl,
substituted benzyl, aromatic or substituted aromatic
ester of aspartic acid or glutamic acid;

AA₁₄ is serine or threonine;

AA₁₅ is glycine or alanine;

AA₁₆ is leucine, isoleucine, methionine or
valine;

30 AA₁₇ is glutamic acid, aspartic acid or an
aliphatic, substituted aliphatic, benzyl,
substituted benzyl, aromatic or substituted aromatic
ester of glutamic acid or aspartic acid;

AA₁₈ is asparagine or glutamine;

35 AA₁₉ is leucine, isoleucine, methionine or
valine; and

AA₂₀ is leucine, isoleucine, methionine or valine.

45. The peptide of Claim 44, wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to the sequence of the HJ loop of GSK3 (SEQ ID NO.: 12) or a subsequence thereof, with the proviso that any two amino acids in the sequence AA₁ through AA₂₀ or the subsequence thereof can vary.
46. The peptide of Claim 44, wherein the sequence AA₁ through AA₂₀ or the subsequence thereof corresponds to the sequence or a subsequence of the HJ loop of GSK3 (SEQ ID NO.: 12), with the proviso that any one amino acid in the sequence AA₁ through AA₂₀ or the subsequence thereof can vary.
47. The peptide of Claim 45 or Claim 46, wherein the peptide comprises an eight amino acid subsequence of the sequence AA₁ through AA₂₀, wherein the subsequence is selected from the group consisting of AA₃ through AA₁₀, AA₇ through AA₁₄ and AA₁₁ through AA₁₈.
48. A method of identifying a peptide which modulates the activity of a serine/threonine kinase comprising the steps of:
- a) providing a peptide, referred to as a "test peptide", comprising a peptide derivative of the HJ loop of said serine/threonine kinase and having from about five to about twenty amino acids or analogs thereof;
 - b) incubating the test peptide with cells having one or more cellular activities controlled by a serine/threonine kinase under conditions suitable for assessing activity of the serine/threonine kinase;

- 5 c) assessing activity of the serine/threonine
 kinase, wherein greater or lesser activity
 compared with the cells grown without
 incubation of the test peptide indicates that
 the peptide modulates activity of the
 serine/threonine kinase.
- 10 49. The method of Claim 48, wherein the activity of the
 serine/threonine kinase is assessed by measuring the
 rate of survival or proliferation of said cells in
 tissue culture.
- 15 50. A method of modulating the activity of a
 serine/threonine kinase in a subject, comprising
 administering a therapeutically effective amount of
 a peptide comprising a peptide derivative of the HJ
 loop of a serine/threonine kinase, wherein:
 a) said peptide has between about five and about
 twenty amino acids or amino acid analogs; and
 b) said peptide modulates activity of the
 serine/threonine kinase.

1/12

1	2	3	4	5	6	7	8	9	10
Y/F	X	L/M	L/M/A/I	X	G/A	X	Hydrophobic	P	F/Y

Figure 1

1	2	3	4	5	6	7	8	9	10
Y	E	M	L/M/A	X	G	X	P	P	F
11	12	13	14	15	16	17	18	19	20
X	A/G	D/E/Q	D/E/Q/N	P/E	D/E/I	D/E/Q	I/L	Y/F	Q/E

Figure 2

SERINE\THREONINE KINASES

RAF	1	Y	F	W															
	2	E	Q	E*	N	D	D*												
	3	L	I	M	V														
	4	M	V	L	I														
	5	T	A	S															
	6	G	A																
	7	E	Q	D	E*	D*													
	8	L	I	M	V														
	9	P	Y	F	W														
	10	S	A	T															
CAPK	11	H	N	D	Q	E	E*												
	12	I	L	M	V														
	13	N	D*	D	Q	E	E*												
	14	N	D*	D	Q	E	E*												
	15	R	X																
	16	D	N	D*	Q	E	E*												
	17	Q	E	E*	N	D													
	18	I	L	M	V														
	19	I	L	M	V														
	20	I	L	M	V														
PKC	1	Y	F	W															
	2	E	Q	E*	D	D*	N												
	3	M	V	L	I														
	4	A	G																
	5	A	V	M	L	I													
	6	G	A																
	7	Y	F	W															
	8	P																	
	9	P	Y	W															
	10	F	Y	W															
BARK1.2	11	G	A																
	12	E	D	Q	N	E*	D*												
	13	E	D	Q	N	E*	D*												
	14	E	Q	E*	N	D													
	15	D	E	Q	N	D*	E*												
	16	D	E	Q	N	D*	E*												
	17	E	D	Q	N	D*	E*												
	18	F	Y	W															
	19	H																	
	20	E	Q	N	D	D*	E*												

Figure 3A

CaMK	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
	Y F W	I L M V	L I M V	L I M V	V L M C I	G A	Y F W	P	P F Y W	W Y F	D N D* Q E D* E*	E Q E* N D* Q E D* E*	D N D* Q E D* E*	H	R K X O	L I M V	Y F W	Q E* D* N	D*	N
POLO	Y F W	T S	L M I V	L I M V	V L I M	G A	K R O X	P	P F Y W	E D Q N E* D*	T S	S T	C T S	L V I M	K O	E D N Q E* D*	T S	Y F W	L I V M	
Akt/ PKB	Y F W	E E* D D*	M L I V	M L I V	C S T	G A	R X	L M I V	P F W Y	Y W F	N Q	Q N	D D* E* E*	H K O	E E* D D*	R X K O	L M I V	F Y W	E E* D D*	
GRK1	Y W F	E E* D D*	M I L V	I M L V	A G	A G	R X	G A	P F W	R X Y	A G	R X	G A	E E*	K O D D*	V M H	E E* I L	N Q D D*	K O H	
GRK4	Y F W	E E* D D*	M I L V	I L M V	Q N	G A	H K O	S T	P F W Y	K O H	K O H	Y F W	K O H D D*	E E*	E D D*	V M I L	K O H	W F Y	E E* D D*	

Figure 3B

GRK5	Y	E	M	I	E	G	Q	S	P	F	R	G	R	K	E	K	V	K	R	E
	F	E*	I	L	E*	A	N	T	F	W	X	A	X	O	E*	O	M	O	X	E*
	W	D	L	M	D					Y			H	H	D	H	I	H		D
		D*	V	V	D*										D*		L			D*
GRK6	Y	E	M	I	A	G	Q	S	P	F	Q	Q	R	K	K	I	I	K	R	E
	F	E*	I	L	G	A	N	T		W	N	N	X	O	O	M	H	O	X	E*
	W	D	L	M							Y			H	H	H	V	H		E*
		D*	V	V													L			D*
GSK3	A	E	L	L	L	G	Q	P	I	F	P	G	D	S	G	V	D	Q	L	V
	G	E*	I	I	I	A	N		L	Y		A	D*	T	A	L	D*	N	I	L
		D	M	M	M				M	W			E		I	E		M	M	I
		D*	V	V	V				V				E*		M	E*		V		M

D* = a substituted or unsubstituted aliphatic, benzylic or aromatic ester of aspartic acid
E* = a substituted or unsubstituted aliphatic, benzylic or aromatic ester of glutamic acid
X = N-nitroarginine, β -cycloarginine, γ -hydroxyarginine, amidinocitroline or 2-amino-4-guanidinobutanoic acid
O = Ornithine

Figure 3C

<u>RAE</u>												
HJ38	AC-	V	M	T	G	Q'	L	P	F	-NH ₂		
J41	AC-	V	M	T	G	E!	L	P	F	-NH ₂		
<u>POLQ</u>												
J42	AC-		M	L	L	G	R	P	F	E!	-NH ₂	
J43	AC-		M	L	L	G	K	P	F	NH ₂		
J43.1	AC-		M	L	L	G	K	P	F	E!	-NH ₂	
J45				Ac-	L	G	R	P	F	E!	T	-NH ₂
J46	AC-		M	L	L	G	R	P	F	E!	T	-NH ₂
<u>AKT/PKB</u>												
J47				Ac-	G	R	L	P	F	N	-NH ₂	
J48	AC-	E!	M	M	G	R	L	P	F	N	-NH ₂	
<u>GSK3</u>												
J29	AC-	L	L	L	G	Q	P	I	F	P	G	-NH ₂

E! - Benzyl Ester of Glutamic Acid

Figure 4

6/12




Figure 5

Activin/TGFbR

ACTRIIA

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K095H101	Myristyl - G G P V D E Y M L P F	NH2

ALK1

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K048H101	Myristyl - G G I V E D Y R P P F	NH2

ALK3

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K098H101	Myristyl - G G I V E E Y Q L P Y	NH2

ALK4

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K099H101	Myristyl - G G Q V H E E Y Q L P Y	NH2

TGFbRII

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K093H101	Myristyl - G G E V K D Y E P P F	NH2

Akt/PKB

Akt1/Raca

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K014H101	Myristyl - G M M S G R L P	NH2

Figure 6A

CAPK

cAPKa

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K004H001	Acetyl M A A G Y P	NH2
K004H002	Acetyl M A A G Y P P F F	NH2

CDK

CDK2

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K049H101	Myristyl - G M V T R R A L F	NH2

CDK4

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K050H101	Myristyl - G M F R R K P L F	NH2

CHK

Chk1

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K088H001	Acetyl M L A G E I L P W D I	NH2
K088H101	Myristyl - G M L A G E L P	NH2
K088H103	Myristyl - G M L A G E L	NH2
K088H104	Myristyl - G M L A G E L P W D	NH2

Figure 6B

DAPK

DAPK

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K092H001	Acetyl I L L S G A S P F L G	NH2

GSK3

GSK3b

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K018H101	Myristyl - G L L L G Q P I	NH2

IAK

Iak1

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K087H001	Acetyl F L V G M P P F	NH2

K087H101	Myristyl - G F L V G M P P	NH2
----------	----------------------------	-----

K087H102	Myristyl - G F L V G M P	NH2
----------	--------------------------	-----

K087H103	Myristyl - G F L V G M P P F E	NH2
----------	--------------------------------	-----

IKK

IKK-1

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K090H101	Myristyl - G I A G Y R P F L	NH2

Figure 6C

IKK-2

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K091H001	Acetyl I T G F R P F L	NH2
K091H101	Myristyl - G I T G F R P F L	NH2

ILK

ILK

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K107H001	Acetyl L V T R E I V	NH2
K107H101	Myristyl - G L V T R E V P F	NH2
K107H102	Myristyl - G L V T R E V	NH2

MARK/p78

MARK1

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K045H101	Myristyl - G L V S G S	NH2
K045H102	Myristyl - G L V S G S L P	NH2

Figure 6D

PKC

PKCb

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K008H001	Acetyl M L A G Q A P F	NH2
K008H101	Myristyl - G M L A G Q A P	NH2
K008H102	Myristyl - G M L A G Q A	NH2
K008H103	Myristyl - G M L A G Q A P F E	NH2

POLO

Plk

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K035H001	Acetyl L L V G K P P F	NH2
K035H101	Myristyl - G L L V G K P P	NH2

SNK

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K038H101	Myristyl - G M L L G R P P F E I	NH2
K038H102	Myristyl - G M L L G R P P	NH2

Figure 6E

RAF
Braf

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K003H103	Myristyl - G L M T G Q L	NH2
K003H104	Myristyl - G L M T G Q L P Y S	NH2

c-Raf

<u>Peptide N_terminal</u>		<u>C_terminal</u>
K001H102	Myristyl - G L M T G E L	NH2
K001H103	Myristyl - G L M T G E L P Y S	NH2

Figure 6F



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/12, C12Q 1/48, A61K 38/45	A3	(11) International Publication Number: WO 98/53050 (43) International Publication Date: 26 November 1998 (26.11.98)
(21) International Application Number: PCT/US98/10319 (22) International Filing Date: 20 May 1998 (20.05.98) (30) Priority Data: 08/861,338 21 May 1997 (21.05.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/861,338 (CIP) Filed on 21 May 1997 (21.05.97) (71) Applicants (for all designated States except US): THE CHILDREN'S MEDICAL CENTER CORPORATION [US/US]; 300 Longwood Street, Boston, MA 02115 (US). YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; Jabotinsky Street 46, P.O. Box 4279, 91042 Jerusalem (IL). (72) Inventor; and (75) Inventor/Applicant (for US only): BEN-SASSON, Shmuel, A. [IL/IL]; Epstein Street 3, 96555 Jerusalem (IL).		(74) Agents: BROOK, David, E. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02173 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 25 February 1999 (25.02.99)
(54) Title: SHORT PEPTIDES WHICH SELECTIVELY MODULATE THE ACTIVITY OF SERINE/THREONINE KINASES (57) Abstract Disclosed are peptides which are peptide derivatives of the HJ loop of a serine/threonine kinase. The peptides can modulate the activity of the serine/threonine kinase. Also disclosed are methods of modulating the activity of a serine/threonine kinase in a subject by administering one of the peptides of the present invention.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

Int l Application No
PCT/US 98/10319

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N9/12 C12Q1/48 A61K38/45

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GHISO J ET AL: "BINDING OF CYSTATIN C TO C4: THE IMPORTANCE OF SENSE-ANTISENSE PEPTIDES IN THEIR INTERACTION" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, no. 4, 1 February 1990, pages 1288-1291, XP000103571 see page 1289, left-hand column, paragraph 2 --- -/--	16

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search

29 October 1998

Date of mailing of the international search report

19/11/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van der Schaal, C

INTERNATIONAL SEARCH REPORT

Int .tional Application No

PCT/US 98/10319

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US Accession no 109:69322, OKADA, YOSHIO ET AL: "Synthesis of Gln-Val-Val-Ala-Gly, a common sequence of thiol proteinase inhibitors, and its derivatives. Relationship between structure and effect on thiol proteinases" XP002082498 see abstract & PEPT. CHEM. (1988), VOLUME DATE 1987 653-6 CODEN: PECHDP;ISSN: 0388-3698,1988,</p>	16
A	<p>HARDIE G. AND HANKS S.: "The protein kinase factsbook I" 1995 , ACADEMIC PRESS , LONDON XP002082497 214500 cited in the application see page 7-20; figure 1 especially page 19 under Subdomain IX</p>	
A	<p>DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US Accession no 120:100177, MCMURRAY, JOHN S. ET AL: "Cyclic peptide substrates of pp60c-src: synthesis and evaluation" XP002082499 see abstract & INT. J. PEPT. PROTEIN RES. (1993), 42(3), 209-15 CODEN: IJPPC3;ISSN: 0367-8377,1993,</p>	2
A	<p>WO 97 14038 A (TERRAPIN TECH INC) 17 April 1997 see the whole document</p>	1,48,49

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 10319

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 50
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
Please see Further Information sheet enclosed.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

The scope of claims 16 - 47 is very broad and speculative. A peptide sequence of which almost each of the 20 amino acids and the total length can vary independently, can not be considered to be a clear and concise definition of patentable subject matter. (Art.6 PCT).

Furthermore the available experimental data actually only comprise a very small amount of the compounds claimed. Therefor claims 16 - 47 can not be considered to represent a permissible generalisation which is fairly based on experimental evidence, that is, they are not adequately supported by the description (Art.6 PCT). Therefor a meaningful and economically feasible search could not encompass the complete subject-matter of the claims. Consequently the search has been limited to the actually tested compounds (Art.17(2)(a)(ii)PCT, PCT Guidelines III,2.1) and thus is only complete for claim 14.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 98/10319

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
W0 9714038 A	17-04-1997	US 5783405 A	21-07-1998
		US 5776716 A	07-07-1998
		AU 7398696 A	30-04-1997

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ ~~FADED TEXT OR DRAWING~~
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ ~~LINE(S) OR MARKS ON ORIGINAL DOCUMENT~~
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.